Intercept Pharmaceuticals PE Ratio 2011-2021 | ICPT

Current and historical p/e ratio for Intercept Pharmaceuticals (ICPT) from 2011 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Intercept Pharmaceuticals PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Intercept Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 17.13 0.00
2021-06-30 19.97 $-5.14 0.00
2021-03-31 23.08 $-6.73 0.00
2020-12-31 24.70 $-8.37 0.00
2020-09-30 41.46 $-9.78 0.00
2020-06-30 47.91 $-10.36 0.00
2020-03-31 62.96 $-10.72 0.00
2019-12-31 123.92 $-10.89 0.00
2019-09-30 66.36 $-10.87 0.00
2019-06-30 79.57 $-10.46 0.00
2019-03-31 111.86 $-10.76 0.00
2018-12-31 100.79 $-10.95 0.00
2018-09-30 126.36 $-12.41 0.00
2018-06-30 83.91 $-13.12 0.00
2018-03-31 61.52 $-14.00 0.00
2017-12-31 58.42 $-14.39 0.00
2017-09-30 58.04 $-14.80 0.00
2017-06-30 121.07 $-15.50 0.00
2017-03-31 113.10 $-15.18 0.00
2016-12-31 108.65 $-16.74 0.00
2016-09-30 164.59 $-15.52 0.00
2016-06-30 142.68 $-14.03 0.00
2016-03-31 128.47 $-12.88 0.00
2015-12-31 149.35 $-9.49 0.00
2015-09-30 165.86 $-7.50 0.00
2015-06-30 241.38 $-7.09 0.00
2015-03-31 282.02 $-3.59 0.00
2014-12-31 156.00 $-15.02 0.00
2014-09-30 236.69 $-14.03 0.00
2014-06-30 236.63 $-13.99 0.00
2014-03-31 329.79 $-16.29 0.00
2013-12-31 68.28 $-3.70 0.00
2013-09-30 69.03 $-5.08 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.569B $0.313B
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76